Triptorelin doesn't prevent chemo-induced ovarian failure

May 27, 2016

(HealthDay)—Triptorelin plus norethisterone (GnRHa) does not prevent chemotherapy-induced premature ovarian failure (POF) in young patients with lymphoma, according to a study published online May 23 in the Journal of Clinical Oncology.

Isabelle Demeestere, M.D., Ph.D., from the Université Libre de Bruxelles in Belgium, and colleagues reported the final analysis of a cohort of 129 patients with lymphoma who were randomized to receive GnRHa or norethisterone alone (control) during chemotherapy. After two, three, four, and five to seven years of follow-up, ovarian function and fertility were reported. Overall, 67 patients (26.21 ± 0.64 years of age) had available data after a median follow-up of 5.33 and 5.58 years in the GnRHa and control groups, respectively.

The researchers found that the risk of POF was significantly increased according to age (P = 0.047), the conditioning regimen for transplant (P = 0.002), and the cumulative dose of cyclophosphamide >5 g/m² (P = 0.019); the risk was not increased with co-administration of GnRHa during chemotherapy (odds ratio, 0.702; P = 0.651). Both groups had similar ovarian reserve, evaluated using anti-Müllerian hormone and follicle-stimulating hormone levels. In the GnRHa and control groups, 53 and 43 percent, respectively, achieved pregnancy (P = 0.467).

"These results reopen the debate about the drug's benefit in that it should not be recommended as standard for fertility preservation in patients with ," the authors write.

Several authors disclosed financial ties to the pharmaceutical industry; triptorelin was provided by the Ipsen Pharmaceutical Group.

Explore further: Triptorelin doesn't avert early ovarian failure in lymphoma

More information: Abstract
Full Text

Related Stories

Triptorelin doesn't avert early ovarian failure in lymphoma

November 7, 2012
(HealthDay)—Treatment of lymphoma patients with the gonadotropin-releasing hormone agonist (GnRHa) triptorelin plus norethisterone does not reduce the rate of chemotherapy-induced premature ovarian failure (POF), according ...

Long-term outcomes of preventing premature menopause during chemotherapy

December 22, 2015
Compared with receiving chemotherapy alone, women with breast cancer who also received the hormonal drug triptorelin to achieve ovarian suppression had a higher long-term probability of ovarian function recovery, without ...

High doses of triptorelin needed for ovarian suppression in SLE

May 4, 2015
(HealthDay)—For female patients with childhood-onset systemic lupus erythematosus (SLE) who require treatment with cyclophosphamide, sustained complete ovarian suppression is achieved in 90 percent of the patients with ...

Comparing chemical and surgical castration for prostate cancer

December 23, 2015
Surgical castration to remove the testicles (orchiectomy) of men with metastatic prostate cancer was associated with lower risks for adverse effects compared with men who underwent medical castration with gonadotropin-releasing ...

Intraperitoneal chemo offers lasting benefit in ovarian cancer

March 27, 2015
(HealthDay)—Intraperitoneal (IP) chemotherapy offers lasting benefit for patients with advanced ovarian cancer, according to a study published online March 23 in the Journal of Clinical Oncology.

Therapy appears to reduce rate of chemotherapy-induced early menopause for women with breast cancer

July 19, 2011
Temporarily suppressing ovarian function with use of the hormone analogue triptorelin reduced the occurrence of early menopause induced by chemotherapy among women with breast cancer, according to a study in the July 20 issue ...

Recommended for you

DNA vaccine leads to immune responses in HPV-related head and neck cancer

September 21, 2018
A therapeutic vaccine can boost antibodies and T cells, helping them infiltrate tumors and fight off human papillomavirus (HPV)-related head and neck cancer. Researchers from the Abramson Cancer Center of the University of ...

In zebrafish, a way to find new cancer therapies, targeting tumor modulators

September 21, 2018
The lab of Leonard Zon, MD, at Boston Children's Hospital has long been interested in making blood stem cells in quantity for therapeutic purposes. Looking for a way to test for their presence in zebrafish, their go-to research ...

Cancer immunotherapy might benefit from previously overlooked immune players

September 20, 2018
Cancer immunotherapy—efforts to boost a patient's own immune system, allowing it to better fight cancer cells on its own—has shown great promise for some previously intractable cancers. Yet immunotherapy doesn't work ...

What can salad dressing tell us about cancer? Think oil and vinegar

September 20, 2018
Researchers led by St. Jude Children's Research Hospital scientists have identified another way the process that causes oil to form droplets in water may contribute to solid tumors, such as prostate and breast cancer. The ...

Novel biomarker found in ovarian cancer patients can predict response to therapy

September 20, 2018
Despite months of aggressive treatment involving surgery and chemotherapy, about 85 percent of women with high-grade wide-spread ovarian cancer will have a recurrence of their disease. This leads to further treatment, but ...

Testing fluorescent tracers used to help surgeons determine edges of breast cancer tumors

September 20, 2018
A team of researchers with members from institutions in The Netherlands and China has conducted a test of fluorescent tracers meant to aid surgeons performing tumor removal in breast cancer patients. In their paper published ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.